CoChat

Long-lasting geroprotection from brief rapamycin treatment in early adulthood by persistently increased intestinal autophagy

Open access

Published version of a preprint

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Abstract

The licensed drug rapamycin has potential to be repurposed for geroprotection. A key challenge is to avoid adverse side effects from continuous dosing. Here we show that geroprotective effects of chronic rapamycin treatment can be obtained with a brief pulse of the drug in early adulthood in female Drosophila and mice. In Drosophila , a brief, early rapamycin treatment of adults extended lifespan and attenuated age-related decline in the intestine to the same degree as lifelong dosing. Lasting memory of earlier treatment was mediated by elevated autophagy in intestinal enterocytes, accompanied by increased levels of intestinal LManV and lysozyme. Brief elevation of autophagy in early adulthood itself induced a long-term increase in autophagy. In mice, a 3-month, early treatment also induced a memory effect, with maintenance similar to chronic treatment, of lysozyme distribution, Man2B1 level in intestinal crypts, Paneth cell architecture and gut barrier function, even 6 months after rapamycin was withdrawn.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s43587-022-00278-w

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Lifespan response to rapamycin treatment declines with the age of onset of the treatment. a, Rapamycin treatment started on day 30 extended lifespan (P = 2.13 × 10−6) to a lesser degree than did lifelong treatment (P = 1.04 × 10−13; Supplementary Table 2). b,c, Rapamycin treatment started on day 45 modestly extended lifespan (b; P = 0.0003; Supplementary Table 1), whereas treatment started on day 60 (c) had no lifespan-extending effect (P = 0.256; Supplementary Table 1). d, Rapamycin treatment from day 1–30 extended lifespan (P = 2.13 × 10−6) as much as did chronic treatment (P = 0.09; Supplementary Table 2). e, Treatment from days 15–30 extended lifespan slightly less than did chronic treatment (d15–30 versus control, P = 7.58 × 10−7; d15–30 versus chronic rapamycin, P = 0.19; Supplementary Table 3). Experiments in Extended Data Fig. 1a–d and Figs. 1e and 2a were run in parallel, thus lifespan data of the control flies are the same. N = 400 flies per condition. Source data
Fig. 1 Lifespan response to rapamycin treatment declines with the age of onset of the treatment. a, Rapamycin treatment started on day 30 extended lifespan (P = 2.13 × 10−6) to a lesser degree than did lifelong treatment (P = 1.04 × 10−13; Supplementary Table 2). b,c, Rapamycin treatment started on day 45 modestly extended lifespan (b; P = 0.0003; Supplementary Table 1), whereas treatment started on day 60 (c) had no lifespan-extending effect (P = 0.256; Supplementary Table 1). d, Rapamycin treatment from day 1–30 extended lifespan (P = 2.13 × 10−6) as much as did chronic treatment (P = 0.09; Supplementary Table 2). e, Treatment from days 15–30 extended lifespan slightly less than did chronic treatment (d15–30 versus control, P = 7.58 × 10−7; d15–30 versus chronic rapamycin, P = 0.19; Supplementary Table 3). Experiments in Extended Data Fig. 1a–d and Figs. 1e and 2a were run in parallel, thus lifespan data of the control flies are the same. N = 400 flies per condition. Source dataCC BY · PubMed Central
Fig. 2 Brief rapamycin treatment early in adulthood extends lifespan and preserves intestinal function as much as does chronic treatment. a, Lifespan of flies chronically or in days 1–15 treated with rapamycin (n = 400 per condition; Supplementary Table 3). b, Experimental design. c, The number of pH3+ cells (arrows) in the gut 45 d after the short-term rapamycin treatment was withdrawn (n = 7–8). d, Midgut turnover rate, as assessed with the esgtsF/O system 20 d after treatment (n = 15–18). e, The number of dpErk+ cells 45 d after rapamycin treatment (n = 10–11). f, Intestinal dysplasia in the gut R2 region of flies carrying epithelial marker Resille-GFP 45 d after short-term rapamycin treatment was terminated (n = 6–8). g, Intestinal barrier function in flies treated with rapamycin chronically or in days 1–15. Data are the mean ± s.e.m. One-way analysis of variance (ANOVA), Bonferroni’s post hoc test. NS, not significant. Source data
Fig. 2 Brief rapamycin treatment early in adulthood extends lifespan and preserves intestinal function as much as does chronic treatment. a, Lifespan of flies chronically or in days 1–15 treated with rapamycin (n = 400 per condition; Supplementary Table 3). b, Experimental design. c, The number of pH3+ cells (arrows) in the gut 45 d after the short-term rapamycin treatment was withdrawn (n = 7–8). d, Midgut turnover rate, as assessed with the esgtsF/O system 20 d after treatment (n = 15–18). e, The number of dpErk+ cells 45 d after rapamycin treatment (n = 10–11). f, Intestinal dysplasia in the gut R2 region of flies carrying epithelial marker Resille-GFP 45 d after short-term rapamycin treatment was terminated (n = 6–8). g, Intestinal barrier function in flies treated with rapamycin chronically or in days 1–15. Data are the mean ± s.e.m. One-way analysis of variance (ANOVA), Bonferroni’s post hoc test. NS, not significant. Source dataCC BY · PubMed Central
Fig. 3 Short-term rapamycin treatment induces lasting autophagy activation. a, Number of punctae stained by LysoTracker and Cyto-ID in 25-day-old flies treated with rapamycin either chronically or in days 1–15 (n = 7). b,c, Immunoblot of autophagy-related proteins, Atg8-I, Atg8-II and Ref-2-P in the fly gut (b) and the head (c) on day 25, 10 d after rapamycin treatment. Data are the mean ± s.e.m. One-way ANOVA; Bonferroni’s multiple-comparison test. n = 4 biological replicates, each consisting of ten flies. Source data
Fig. 3 Short-term rapamycin treatment induces lasting autophagy activation. a, Number of punctae stained by LysoTracker and Cyto-ID in 25-day-old flies treated with rapamycin either chronically or in days 1–15 (n = 7). b,c, Immunoblot of autophagy-related proteins, Atg8-I, Atg8-II and Ref-2-P in the fly gut (b) and the head (c) on day 25, 10 d after rapamycin treatment. Data are the mean ± s.e.m. One-way ANOVA; Bonferroni’s multiple-comparison test. n = 4 biological replicates, each consisting of ten flies. Source dataCC BY · PubMed Central
Fig. 4 Enterocyte-specific autophagy induction mediates lifespan extension and gut barrier protection by short-term rapamycin treatment. a,b, Chronic (P = 1.53 × 10−5) and brief rapamycin (P = 8.8 × 10−10) treatment extended lifespan of control flies, but not of flies expressing RNAi against Atg5 in enterocytes (chronic. P = 0.25; d1–15, P = 0.097; Supplementary Table 5). n = 400. c,d, Chronic (P = 3.4 × 10−6) and brief (P = 8.2 × 10−13) rapamycin treatment extended lifespan of control flies and flies with Atg5-RNAi specifically in ISCs (chronic, P = 0.001; d1–15, P = 5.4 × 10−12; Supplementary Table 6). n = 200. Log-rank test and Cox proportional hazard (CPH) analysis. e,f, Chronic and brief rapamycin treatment reduced the proportion of blue flies in the control group, but not in flies with enterocyte-specific Atg5-RNAi, on day 65. Rapamycin × genotype interaction (chronic, P = 0.057; d1–15, P = 0.020). n = 19–21 vials per condition with 20 flies in each vial. Data are the mean ± s.e.m. Two-way ANOVA followed by Bonferroni’s post hoc test. Source data
Fig. 4 Enterocyte-specific autophagy induction mediates lifespan extension and gut barrier protection by short-term rapamycin treatment. a,b, Chronic (P = 1.53 × 10−5) and brief rapamycin (P = 8.8 × 10−10) treatment extended lifespan of control flies, but not of flies expressing RNAi against Atg5 in enterocytes (chronic. P = 0.25; d1–15, P = 0.097; Supplementary Table 5). n = 400. c,d, Chronic (P = 3.4 × 10−6) and brief (P = 8.2 × 10−13) rapamycin treatment extended lifespan of control flies and flies with Atg5-RNAi specifically in ISCs (chronic, P = 0.001; d1–15, P = 5.4 × 10−12; Supplementary Table 6). n = 200. Log-rank test and Cox proportional hazard (CPH) analysis. e,f, Chronic and brief rapamycin treatment reduced the proportion of blue flies in the control group, but not in flies with enterocyte-specific Atg5-RNAi, on day 65. Rapamycin × genotype interaction (chronic, P = 0.057; d1–15, P = 0.020). n = 19–21 vials per condition with 20 flies in each vial. Data are the mean ± s.e.m. Two-way ANOVA followed by Bonferroni’s post hoc test. Source dataCC BY · PubMed Central
Fig. 5 Short-term Atg1 overexpression induces lasting autophagy activation and extends lifespan to the same degree as short rapamycin treatment. a, Immunoblot of intestinal Ref-2-P of flies treated with rapamycin from days 1–15 in combination with enterocyte-specific overexpression of Atg1 in days 1–15, measured 10 d after treatment (n = 4). Genotype × rapamycin interaction (P = 0.03). b,c, Chronic (P = 3.6 × 10−11) and day 1–15 (P = 6.7 × 10−5) overexpression of Atg1 specifically in enterocytes extended lifespan to the same degree as rapamycin (chronic, P = 0.50; d1–15, P = 0.69; Supplementary Table 7). n = 160–200. Log-rank test and CPH analysis. d,e, Chronic and day 1–15 overexpression of Atg1 reduced the proportion of blue flies to the same degree as rapamycin treatment, on day 65. Rapamycin × genotype interaction for chronic overexpression (P = 0.02). n = 10 vials per condition with 20 flies per vial. Data are the mean ± s.e.m. Two-way ANOVA; Bonferroni’s multiple-comparison test.
Fig. 5 Short-term Atg1 overexpression induces lasting autophagy activation and extends lifespan to the same degree as short rapamycin treatment. a, Immunoblot of intestinal Ref-2-P of flies treated with rapamycin from days 1–15 in combination with enterocyte-specific overexpression of Atg1 in days 1–15, measured 10 d after treatment (n = 4). Genotype × rapamycin interaction (P = 0.03). b,c, Chronic (P = 3.6 × 10−11) and day 1–15 (P = 6.7 × 10−5) overexpression of Atg1 specifically in enterocytes extended lifespan to the same degree as rapamycin (chronic, P = 0.50; d1–15, P = 0.69; Supplementary Table 7). n = 160–200. Log-rank test and CPH analysis. d,e, Chronic and day 1–15 overexpression of Atg1 reduced the proportion of blue flies to the same degree as rapamycin treatment, on day 65. Rapamycin × genotype interaction for chronic overexpression (P = 0.02). n = 10 vials per condition with 20 flies per vial. Data are the mean ± s.e.m. Two-way ANOVA; Bonferroni’s multiple-comparison test.CC BY · PubMed Central
Fig. 6 Persistent increase in LManV mediates the ‘memory of autophagy’ and reduced age-related gut pathology induced by short-term rapamycin treatment. a,b, Overexpression of RNAi against LManV in enterocytes in days 1–15 abolished the increase in LysoTracker staining (a) and reduction in gut pathology (b) induced by short-term rapamycin treatment (n = 7 flies). c,d, overexpression of LManV in enterocytes in days 1–15 increased LysoTracker staining (c) and reduced age-related gut pathology (d) to the same degree as chronic overexpression of LManV (n = 9–10 flies). e, Chronic and short-term rapamycin treatment increased intestinal lysozyme level irrespective of tetracycline treatment (n = 6 flies). f, Chronic and short-term overexpression of LManV increased lysozyme levels to the same degree (n = 8–9 flies). g, Overexpression of RNAi against LManV in enterocytes in days 1–15 abolished the increase in lysozyme level induced by rapamycin treatment in days 1–15 (n = 8–9 flies). h, Overexpression of RNAi against Atg5 in enterocytes in days 1–15 abolished the increase in lysozyme level induced by rapamycin treatment in days 1–15 (n = 6 flies). Data are the mean ± s.e.m. One-way (c, d and f) and two-way (a, b, e, g and h) ANOVA; Bonferroni’s multiple-comparison test.
Fig. 6 Persistent increase in LManV mediates the ‘memory of autophagy’ and reduced age-related gut pathology induced by short-term rapamycin treatment. a,b, Overexpression of RNAi against LManV in enterocytes in days 1–15 abolished the increase in LysoTracker staining (a) and reduction in gut pathology (b) induced by short-term rapamycin treatment (n = 7 flies). c,d, overexpression of LManV in enterocytes in days 1–15 increased LysoTracker staining (c) and reduced age-related gut pathology (d) to the same degree as chronic overexpression of LManV (n = 9–10 flies). e, Chronic and short-term rapamycin treatment increased intestinal lysozyme level irrespective of tetracycline treatment (n = 6 flies). f, Chronic and short-term overexpression of LManV increased lysozyme levels to the same degree (n = 8–9 flies). g, Overexpression of RNAi against LManV in enterocytes in days 1–15 abolished the increase in lysozyme level induced by rapamycin treatment in days 1–15 (n = 8–9 flies). h, Overexpression of RNAi against Atg5 in enterocytes in days 1–15 abolished the increase in lysozyme level induced by rapamycin treatment in days 1–15 (n = 6 flies). Data are the mean ± s.e.m. One-way (c, d and f) and two-way (a, b, e, g and h) ANOVA; Bonferroni’s multiple-comparison test.CC BY · PubMed Central
Fig. 7 Short-term rapamycin exposure maintains gut barrier function and Paneth cell architecture to the same degree as lifelong treatment in mice. a, Experimental design. b, Plasma LBP levels during aging and 6 months after rapamycin treatment was terminated (n = 10–15 mice). c, TJ pathology score: I, narrow and electron-dense TJs; II, reduced electron density, but no dilations within TJs; III, low electron density and dilated TJs. Proportion of intact TJs during aging and 6 months post-rapamycin-treatment (n = 4–7 mice). d, The proportion of Paneth cells with diffuse lysozyme staining was increased in aged mice and rapamycin reduced the proportion of Paneth cells (arrows) with diffuse lysozyme staining, which remained reduced 6 months after treatment (n = 4). e, Proportion of hypodense Paneth cell granules in mouse jejunum during aging and 6 months after rapamycin treatment was withdrawn. n = 4. Data are the mean ± s.e.m (b and e) and s.d. (c; rapa treatment). One-way ANOVA; Bonferroni’s multiple-comparison test.
Fig. 7 Short-term rapamycin exposure maintains gut barrier function and Paneth cell architecture to the same degree as lifelong treatment in mice. a, Experimental design. b, Plasma LBP levels during aging and 6 months after rapamycin treatment was terminated (n = 10–15 mice). c, TJ pathology score: I, narrow and electron-dense TJs; II, reduced electron density, but no dilations within TJs; III, low electron density and dilated TJs. Proportion of intact TJs during aging and 6 months post-rapamycin-treatment (n = 4–7 mice). d, The proportion of Paneth cells with diffuse lysozyme staining was increased in aged mice and rapamycin reduced the proportion of Paneth cells (arrows) with diffuse lysozyme staining, which remained reduced 6 months after treatment (n = 4). e, Proportion of hypodense Paneth cell granules in mouse jejunum during aging and 6 months after rapamycin treatment was withdrawn. n = 4. Data are the mean ± s.e.m (b and e) and s.d. (c; rapa treatment). One-way ANOVA; Bonferroni’s multiple-comparison test.CC BY · PubMed Central
Fig. 8 Short-term rapamycin exposure increases the number of granules positive for both lysozyme and p62 in Paneth cells and the number of Man2B1+ punctae in intestinal crypts to the same degree as lifelong treatment in mice. a, The number of lysozyme+/p62+ granules per Paneth cell was increased by rapamycin and remained increased 6 months after the treatment was withdrawn, at 12 months of age (n = 4 mice; at least ten Paneth cells per mouse were analyzed and the average value per mouse was used). White dashed lines denote Paneth cells. b, Number of Man2B1+ punctae was increased by rapamycin and remained increased 6 months after treatment, at 12 months of age (n = 6–10 mice). White dashed lines denote crypt units. Scale bar, 20 μm. Data are the mean ± s.e.m. One-way ANOVA; Bonferroni’s multiple-comparison test.
Fig. 8 Short-term rapamycin exposure increases the number of granules positive for both lysozyme and p62 in Paneth cells and the number of Man2B1+ punctae in intestinal crypts to the same degree as lifelong treatment in mice. a, The number of lysozyme+/p62+ granules per Paneth cell was increased by rapamycin and remained increased 6 months after the treatment was withdrawn, at 12 months of age (n = 4 mice; at least ten Paneth cells per mouse were analyzed and the average value per mouse was used). White dashed lines denote Paneth cells. b, Number of Man2B1+ punctae was increased by rapamycin and remained increased 6 months after treatment, at 12 months of age (n = 6–10 mice). White dashed lines denote crypt units. Scale bar, 20 μm. Data are the mean ± s.e.m. One-way ANOVA; Bonferroni’s multiple-comparison test.CC BY · PubMed Central
Extended Data Fig. 1 Brief rapamycin treatment inhibits ISC division and epithelial turnover rate to the late stages of life. a-b, Rapamycin treatment from day 1-15 reduced pH3+ cell number 10 (a, n = 7) and 30 (b, n = 8-10) days post-treatment to the same degree as rapamycin chronic exposure. c, Rapamycin concentration was increased in the guts of 25-day-old flies chronically treated with rapamycin but was absent from the intestine 10-days after rapamycin treatment was terminated. n = 6-7. d, Turnover of intestinal epithelium was reduced 10 days after the treatment termination as assessed by esgts F/O system activation (at 29 °C). Data are mean ± s.e.m. One-way ANOVA followed by Bonferroni’s post-test.
Extended Data Fig. 1 Brief rapamycin treatment inhibits ISC division and epithelial turnover rate to the late stages of life. a-b, Rapamycin treatment from day 1-15 reduced pH3+ cell number 10 (a, n = 7) and 30 (b, n = 8-10) days post-treatment to the same degree as rapamycin chronic exposure. c, Rapamycin concentration was increased in the guts of 25-day-old flies chronically treated with rapamycin but was absent from the intestine 10-days after rapamycin treatment was terminated. n = 6-7. d, Turnover of intestinal epithelium was reduced 10 days after the treatment termination as assessed by esgts F/O system activation (at 29 °C). Data are mean ± s.e.m. One-way ANOVA followed by Bonferroni’s post-test.CC BY · PubMed Central
Extended Data Fig. 2 Effect of short-term rapamycin treatment on tissue-specific TORC1 activity and lifespan of flies over-expressing constitutively active S6K in the gut. a-d, Rapamycin treatment initiated on day 30 down-regulated TORC1 activity within 48 h and terminating rapamycin treatment on day 30 de-repressed TORC1 activity back to the levels of control flies within 48 h in heads, muscle, fat body and gut. Data are mean ± s.e.m. One-way ANOVA; Tukey’s multiple comparison test. N = 3 biological replicates, each consisting of 15 flies. e-f, Chronic (p = 9.95 ×10-05) and short-term (p = 0.029) rapamycin treatment extended lifespan of control flies and of flies over-expressing constitutively active S6K in the gut (chronic: p = 0.002, short-term treatment: p = 0.02, see also Supplementary Table 4). N = 200 flies per experimental group. Log-rank test and CPH analysis.
Extended Data Fig. 2 Effect of short-term rapamycin treatment on tissue-specific TORC1 activity and lifespan of flies over-expressing constitutively active S6K in the gut. a-d, Rapamycin treatment initiated on day 30 down-regulated TORC1 activity within 48 h and terminating rapamycin treatment on day 30 de-repressed TORC1 activity back to the levels of control flies within 48 h in heads, muscle, fat body and gut. Data are mean ± s.e.m. One-way ANOVA; Tukey’s multiple comparison test. N = 3 biological replicates, each consisting of 15 flies. e-f, Chronic (p = 9.95 ×10-05) and short-term (p = 0.029) rapamycin treatment extended lifespan of control flies and of flies over-expressing constitutively active S6K in the gut (chronic: p = 0.002, short-term treatment: p = 0.02, see also Supplementary Table 4). N = 200 flies per experimental group. Log-rank test and CPH analysis.CC BY · PubMed Central
Extended Data Fig. 3 Effect of brief rapamycin treatment on the number of lysotracker + punctae in the gut 30-days post-treatment. Rapamycin induced lysotracker-stained punctae in the gut of 45-days old flies, and these stayed induced 30-days post-treatment. N = 4-5. Data are mean ± s.e.m. One-way ANOVA; Bonferroni’s multiple comparison test.
Extended Data Fig. 3 Effect of brief rapamycin treatment on the number of lysotracker + punctae in the gut 30-days post-treatment. Rapamycin induced lysotracker-stained punctae in the gut of 45-days old flies, and these stayed induced 30-days post-treatment. N = 4-5. Data are mean ± s.e.m. One-way ANOVA; Bonferroni’s multiple comparison test.CC BY · PubMed Central
Extended Data Fig. 4 Increased expression of histones by chronic rapamycin treatment is not responsible for the effects of short-term rapamycin treatment on lifespan and gut health. a, Immunoblot of histone H3 in the fly gut on day 30, 15-days post-rapamycin-treatment (n = 4). b, The accumulation of chromatin at the nuclear envelope in ECs disappeared 15 days after d1-15 treatment was terminated (n = 6 guts). c, Chronic but not d1-15 over-expression of histones H3/H4 specifically in enterocytes extended lifespan (chronic: p = 7.39 ×10-06; d1-15 treatment: p = 0.60. n = 160-200 flies per experimental group. Log-rank test. d, Number of punctae stained by LysoTracker in 30-day old flies overexpressing H3/H4 specifically in enterocytes chronically or in days 1-15 (n = 7). e, The number of pH3+ cells in the gut 30 days after short-term rapamycin treatment was withdrawn (n = 23-25). f, Intestinal dysplasia in gut R2 region of flies 30-days after short-term rapamycin treatment was terminated (n = 16-20). Data are mean ± s.e.m. One-way ANOVA; Bonferroni’s multiple comparison test.
Extended Data Fig. 4 Increased expression of histones by chronic rapamycin treatment is not responsible for the effects of short-term rapamycin treatment on lifespan and gut health. a, Immunoblot of histone H3 in the fly gut on day 30, 15-days post-rapamycin-treatment (n = 4). b, The accumulation of chromatin at the nuclear envelope in ECs disappeared 15 days after d1-15 treatment was terminated (n = 6 guts). c, Chronic but not d1-15 over-expression of histones H3/H4 specifically in enterocytes extended lifespan (chronic: p = 7.39 ×10-06; d1-15 treatment: p = 0.60. n = 160-200 flies per experimental group. Log-rank test. d, Number of punctae stained by LysoTracker in 30-day old flies overexpressing H3/H4 specifically in enterocytes chronically or in days 1-15 (n = 7). e, The number of pH3+ cells in the gut 30 days after short-term rapamycin treatment was withdrawn (n = 23-25). f, Intestinal dysplasia in gut R2 region of flies 30-days after short-term rapamycin treatment was terminated (n = 16-20). Data are mean ± s.e.m. One-way ANOVA; Bonferroni’s multiple comparison test.CC BY · PubMed Central
Extended Data Fig. 5 Rapamycin induces lasting changes in proteome of the gut. GO term analysis of proteins enriched by rapamycin treatment on day 25 that were also enriched 10 days after the drug was withdrawn.
Extended Data Fig. 5 Rapamycin induces lasting changes in proteome of the gut. GO term analysis of proteins enriched by rapamycin treatment on day 25 that were also enriched 10 days after the drug was withdrawn.CC BY · PubMed Central
Extended Data Fig. 6 Intestinal LManV mRNA levels. Rapamycin treatment increased intestinal LManV mRNA, which stayed increased 10-days after the treatment was terminated. N = 4. Data are mean ± s.e.m. One-way ANOVA; Dunnett’s multiple comparison test.
Extended Data Fig. 6 Intestinal LManV mRNA levels. Rapamycin treatment increased intestinal LManV mRNA, which stayed increased 10-days after the treatment was terminated. N = 4. Data are mean ± s.e.m. One-way ANOVA; Dunnett’s multiple comparison test.CC BY · PubMed Central
Extended Data Fig. 7 Persistent increase in BCAT mediates the ‘memory of autophagy’, and partially mediates gut pathology and lifespan induced by short-term rapamycin treatment. a-b, Number of LysoTracker stained punctae in intestines (a) and gut pathology (b) of flies treated with rapamycin from day 1-15 followed by over-expression of RNAi against BCAT (n = 5-7). Data are mean ± s.e.m. Two-way ANOVA; Bonferroni’s multiple comparison test. c, Brief rapamycin (p = 7.8 ×10-4) treatment extended lifespan of control flies, but not of flies expressing RNAi against BCAT in enterocytes (p = 0.14, see also Supplementary Table 9). Log-rank test. n = 180.
Extended Data Fig. 7 Persistent increase in BCAT mediates the ‘memory of autophagy’, and partially mediates gut pathology and lifespan induced by short-term rapamycin treatment. a-b, Number of LysoTracker stained punctae in intestines (a) and gut pathology (b) of flies treated with rapamycin from day 1-15 followed by over-expression of RNAi against BCAT (n = 5-7). Data are mean ± s.e.m. Two-way ANOVA; Bonferroni’s multiple comparison test. c, Brief rapamycin (p = 7.8 ×10-4) treatment extended lifespan of control flies, but not of flies expressing RNAi against BCAT in enterocytes (p = 0.14, see also Supplementary Table 9). Log-rank test. n = 180.CC BY · PubMed Central
Extended Data Fig. 8 Effects of ageing and chronic and short-term rapamycin treatment on TJ. a-c, Tight junction pathology score: I - narrow and electron dense TJs (a); II - reduced electron density, but no dilations within TJs (b); III - low electron density and dilated TJs (c). d, Number of compromised TJs increased by 7 months of age compared to 3 months old mice (3 M v. 7 M: p = 0.0149; 3 M v. 12 M: p = 0.002; 3 M v. 22-24 M: p = 0.0009; 7 M v. 12 M: ns; 12 M v. 22-24 M: ns). e, Rapamycin reduced the percentage of compromised TJs (class II and III) in mouse jejunum (control v. rapa chronic: p = 0.0199; control v. rapa 3-6 M: 0.0405). Numbers of mice are indicated above each bar; at least 10 TJs per mouse were analyzed.
Extended Data Fig. 8 Effects of ageing and chronic and short-term rapamycin treatment on TJ. a-c, Tight junction pathology score: I - narrow and electron dense TJs (a); II - reduced electron density, but no dilations within TJs (b); III - low electron density and dilated TJs (c). d, Number of compromised TJs increased by 7 months of age compared to 3 months old mice (3 M v. 7 M: p = 0.0149; 3 M v. 12 M: p = 0.002; 3 M v. 22-24 M: p = 0.0009; 7 M v. 12 M: ns; 12 M v. 22-24 M: ns). e, Rapamycin reduced the percentage of compromised TJs (class II and III) in mouse jejunum (control v. rapa chronic: p = 0.0199; control v. rapa 3-6 M: 0.0405). Numbers of mice are indicated above each bar; at least 10 TJs per mouse were analyzed.CC BY · PubMed Central
Extended Data Fig. 9 Rapamycin does not significantly affect the number of p62 punctae in the villi region of small intestine. a-d, p62 punctae in villi of small intestine. n = 4-5 mice, 50 or more cells in 5 different villi per mouse were analyzed. Data are mean ± s.e.m. One-way ANOVA, Bonferroni’s post-test. Scale is 15 μm.
Extended Data Fig. 9 Rapamycin does not significantly affect the number of p62 punctae in the villi region of small intestine. a-d, p62 punctae in villi of small intestine. n = 4-5 mice, 50 or more cells in 5 different villi per mouse were analyzed. Data are mean ± s.e.m. One-way ANOVA, Bonferroni’s post-test. Scale is 15 μm.CC BY · PubMed Central
Extended Data Fig. 10 Brief rapamycin treatment improves regenerative capacity of the mammalian intestinal epithelium. a, Experimental design. b-c, Rapamycin increased organoid forming potential of intestinal crypts (arrows) and (j), formation of de novo crypts (white arrowheads), which remained increased 2 months post-treatment (n = 6 mice). Data are mean ± s.d. Two-sided student t-test.
Extended Data Fig. 10 Brief rapamycin treatment improves regenerative capacity of the mammalian intestinal epithelium. a, Experimental design. b-c, Rapamycin increased organoid forming potential of intestinal crypts (arrows) and (j), formation of de novo crypts (white arrowheads), which remained increased 2 months post-treatment (n = 6 mice). Data are mean ± s.d. Two-sided student t-test.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 57 references

Cited by

See all 135

Metadata

Authors
Juricic, P., Lu, Y.-X., Leech, T., Drews, L. F., Paulitz, J., Lu, J., Nespital, T., Azami, S., Regan, J. C., Funk, E., Fröhlich, J., Grönke, S., & Partridge, L.
Affiliations
  • Max Planck Institute for Biology of Ageing (DE)
  • University College London (GB)
Corresponding author
Partridge, Linda
Venue
Nature Aging
Published
2022-08-29
Volume
2
Issue
9
Pages
824-836
ISSN
2662-8465 (ISSN-L)
OpenAlex
W4293475801
Cited by
118
References
57
Citations by year
2026: 15 · 2025: 29 · 2024: 38 · 2023: 30 · 2022: 6
FWCI
8.63
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Aging (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by)
  • UCL Discovery (University College London) (submittedVersion)
Funders
  • European Commission (2007–2013, 741989, FP7 2007-2013, HORIZON2020, FP7/2007)
  • Max-Planck-Gesellschaft
  • Eötvös Loránd Tudományegyetem
  • FP7 Ideas: European Research Council (268739)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords
rapamycin, lifespan extension, drug repurposing, memory effects, Paneth cells, lysozyme, intestinal barrier, aging, Drosophila, mice
MeSH terms
Animals, Autophagy, Drosophila, Female, Muramidase, Paneth Cells, Sirolimus, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-lasting geroprotection from brief rapamycin treatment in early adulthood by persistently increased intestinal autophagy. https://app.cochat.ai/papers/10.1038/s43587-022-00278-w
The paper
Juricic, P., Lu, Y.-X., Leech, T., Drews, L. F., Paulitz, J., Lu, J., Nespital, T., Azami, S., Regan, J. C., Funk, E., Fröhlich, J., Grönke, S., & Partridge, L. (2022). Long-lasting geroprotection from brief rapamycin treatment in early adulthood by persistently increased intestinal autophagy. Nature Aging. https://doi.org/10.1038/s43587-022-00278-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.